GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharma FY26 Consolidated Profit Rs. 103598 Lakhs, Rs. 57 Dividend
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 13 May 2026, 02:54 PM IST · BSE ID: dc9d63d4-8dd3-4714-9271-145bb695c44b
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its full-year financial results, saw higher profit, and declared a dividend of Rs. 57 per share.
🤖 AI Summary
- Board approved Audited Consolidated Financial Results for year ended March 31, 2026.
- Profit for the year ended March 31, 2026, rose to Rs. 103598 Lakhs.
- A final dividend of Rs. 57 per equity share (face value Rs. 10) was recommended.
- The 101st Annual General Meeting is scheduled for June 30, 2026.
- Record Date for final dividend entitlement is Friday, May 29, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Profit for the year (FY26)
Rs. 103598 Lakhs
11.68%
Consolidated Profit for the year (FY25)
Rs. 92758 Lakhs
Final Dividend per share
Rs. 57/-
Consolidated Revenue from operations (FY26)
Rs. 382167 Lakhs
1.93%
Consolidated Revenue from operations (FY25)
Rs. 374921 Lakhs
🏢 How This Affects the Company
Consolidated Profit for the year increased to Rs. 103598 Lakhs for FY26 compared to Rs. 92758 Lakhs in FY25. Total Assets as of March 31, 2026, stood at Rs. 432387 Lakhs, up from Rs. 410808 Lakhs as of March 31, 2025.
The company confirmed it does not fall under the Large Corporate category as of March 31, 2026, based on specified debt and borrowing criteria.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must hold shares in dematerialized or physical form by the Record Date of May 29, 2026, to be eligible for the final dividend.
👤
Who Is Affected
Shareholders holding equity shares of GlaxoSmithKline Pharmaceuticals Ltd as of the close of business hours on Friday, May 29, 2026, will be entitled to the final dividend of Rs. 57 per share.
🔍
Management Signal
The recommendation of a final dividend reflects the management's confidence in the company's financial performance for the concluded fiscal year.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
101st Annual General Meeting on June 30, 2026, for dividend approval.
Dividend payment on or after July 1, 2026.
Next quarterly financial results for Q1 FY27.
LOW RISK
The filing reports full-year financial results and a dividend declaration.
💡 Investor Takeaway
GlaxoSmithKline Pharmaceuticals Ltd reported full-year consolidated profit of Rs. 103598 Lakhs for FY26, a 11.68% increase from Rs. 92758 Lakhs in FY25. The Board recommended a final dividend of Rs. 57 per equity share for FY26.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Profit for the year ended March 31, 2026, increased to Rs. 103598 Lakhs from Rs. 92758 Lakhs in the prior year.
- Revenue from operations for the year ended March 31, 2026, increased to Rs. 382167 Lakhs from Rs. 374921 Lakhs.
⚠️ Concerns
- Consolidated Revenue from operations for the quarter ended March 31, 2026, decreased to Rs. 99530 Lakhs from Rs. 104126 Lakhs in the preceding quarter.
- Cash and cash equivalents decreased by Rs. 7626 Lakhs in operating activities for the year ended March 31, 2026, compared to the prior year.
📅 Company Track Record
Previous filing on May 13, 2026, indicated FY26 Consolidated Profit rose to Rs. 103598 Lakhs and a Rs. 57 final dividend was declared, which is now confirmed and detailed in this outcome of board meeting.
Based on publicly available historical data. For context only.